Table 1.
The characteristics of the 78 patients who underwent whole-brain radiation therapy
| Age, yrs.; mean (SD): | |
|---|---|
| Total | 61.8 (11.5) |
| < 65 | 45 (58) |
| ≥ 65 | 33 (42) |
| Gender: | |
| Male | 43 (55) |
| Female | 35 (45) |
| Primary cancer: | |
| Lung, non-small-cell | 36 (46) |
| Breast | 12 (15) |
| Lung, small-cell | 6 (8) |
| Others | 24 (31) |
| KPS: | |
| 100–90 | 26 (33) |
| 80 | 24 (31) |
| 70 | 16 (21) |
| 60 | 12 (15) |
| No. of brain metastases: | |
| Solitary | 17 (22) |
| Oligo (2–4) | 16 (21) |
| Multiple (5 = <) | 34 (43) |
| Meningeal carcinomatosis | 11 (14) |
| GPA: | |
| 4.0–3.0 | 5 (6) |
| 2.5–2.0 | 20 (26) |
| 1.5–1.0 | 32 (51) |
| 0.5–0.0 | 21 (27) |
| WBRT schedule: | |
| 35 Gy/14 fr | 63 (81) |
| 30 Gy/10 fr | 7 (9) |
| Others | 5 (6) |
| Uncompleted | 3 (4) |
| Treatment: | |
| WBRT only | 47 (60) |
| WBRT + SRS | 11 (14) |
| WBRT + Surgery (+/−SRS) | 20 (26) |
| Systemic therapies prior to WBRT | |
| No | 23 (29) |
| Yes | 55 (71) |
| Cytotoxic chemotherapy | 50 (64) |
| Molecular targeted therapy | 25 (32) |
| Hormonal therapy | 7 (9) |
| Immunotherapy | 2 (3) |
| No. of examinations: | |
| 1: BL only | 37 (48) |
| 2: BL and 4 mos. | 12 (15) |
| 3: BL, 4 mos. and 8 mos. | 29 (37) |
| Examination compliance:%, (/): | |
| At 4 mos. | 85% (41/48) |
| At 8 mos. | 81% (29/36) |
Data are n (%) unless otherwise noted. KPS Karnofsky Performance Status, GPA Graded Prognosis Assessment, WBRT whole-brain radiotherapy, SRS stereotactic radiosurgery, BL baseline, PD progressive disease